Montefiore's Institute for Reproductive Medicine and HealthMay 3, 2019

FDA 483 - Montefiore's Institute for Reproductive Medicine and Health - May 03, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Montefiore's Institute for Reproductive Medicine and Health

Record Details

An FDA inspection of Montefiore's Institute for Reproductive Medicine and Health in Hartsdale, NY, revealed two significant observations related to human reproductive tissue. The firm failed to properly determine and document the eligibility of oocyte donors, specifically by not testing for West Nile Virus. Additionally, the firm's standard operating procedures for egg donor screening were not revised to include seasonal West Nile Virus testing.

Company: Montefiore's Institute for Reproductive Medicine and Health
Inspection Date: May 3, 2019
Product Type: Biologics
Office: Division of Human and Animal Food Operations - East I
Person: Anthony N. Onianwa (Investigator)

Open in Dashboard

ID · 8ec76984-a358-47fb-a632-f8ae5e62b858